WSS25 is a sulfated polysaccharide that inhibits angiogenesis. However, the mechanism underlying the regulation of angiogenesis by WSS25 is not well understood. Using microRNA (miRNA) microarray analysis, a total of 25 miRNAs were found to be upregulated and 12 (including miR-210) downregulated by WSS25 in human microvascular endothelial cells (HMEC-1). Interestingly, Dicer, a key enzyme for miRNA biosynthesis, was downregulated by WSS25 in HMEC-1 cells. Further studies indicated that HMEC-1 cell tube formation and miR-210 expression were suppressed while Ephrin-A3 expression was enhanced by the silencing of Dicer. In contrast, HMEC-1 cell tube formation and miR-210 expression were induced while Ephrin-A3 expression was suppressed by Dicer overexpression. Moreover, miR-210 was downregulated while Ephrin-A3 was upregulated by WSS25 in HMEC-1 cells. HMEC-1 cell migration and tube formation were arrested, while Ephrin-A3 expression was augmented by anti-miR-210. In addition, HMEC-1 cell tube formation was significantly attenuated or augmented when Ephrin-A3 was overexpressed or silenced, respectively. Nevertheless, the tube formation blocked by WSS25 could be partially rescued by manipulation of Dicer, miR-210 and Ephrin-A3. These results suggest a new pathway whereby WSS25 inhibits angiogenesis via suppression of Dicer, leading to downregulation of miR-210 and upregulation of Ephrin-A3.
Introduction
Angiogenesis is a physiological process involving the growth of new blood vessels from pre-existing vessels (Folkman and Shing 1992) . It is a finely tuned balance between angiogenic factors and antiangiogenic factors. Imbalance of these factors will lead to abnormal growth of blood vessels, which contributes to many angiogenic diseases such as tumors, rheumatoid arthritis and ischemic stroke (Folkman 1974; Paleolog 2002) . Multiple steps are involved in angiogenesis, including cell proliferation, cell migration and capillary tube formation.
Growth factors, cytokines and morphogens are well-known as angiogenesis regulators. Recently, microRNAs (miRNAs) have been shown to be a new family of angiogenesis regulators. MiRNAs are small noncoding RNAs catalyzed by Dicer, the processing enzyme required for the maturation of miRNAs. In mammalian cells, small RNAs are processed in the nucleus into hairpin RNAs by the protein Drosha (Lee et al. 2003; Denli et al. 2004 ). Then these pre-miRNAs are transported to the cytoplasm, via an exportin 5-dependent mechanism, where they are digested by a second doublestranded specific ribonuclease called Dicer (Hutvagner et al. 2001) . The mature forms of miRNA are 18-24 nucleotides in length (Martello et al. 2010) . MiRNAs have been identified in a variety of organisms and have been demonstrated to regulate expression of various different genes, including angiogenesis regulators, through binding to complementary sequences of the 3′ untranslated region (3′UTR) of target mRNAs as posttranscriptional modulators (Bartel 2004; He and Hannon 2004) . The roles of miRNAs in angiogenesis have been evaluated (Poliseno et al. 2006; Wang and Olson 2009) . However, information regarding the role of specific miRNAs in angiogenesis is still very limited (Hua et al. 2006; Fish et al. 2008; Kuehbacher et al. 2008) . Recently, miR-210 has been demonstrated to be associated with angiogenesis in human umbilical vein endothelial cells (HUVECs) in hypoxia via targeting of Ephrin-A3 (Fasanaro et al. 2008) .
In a previous report, we isolated an alpha-D-(1-4) glucan with an alpha-D-(1-4) branch periodically at O-6 on every 18th glucose residue from the well-known Chinese herb Gastrodia elata Bl. WSS25 is a sulfated derivative of this glucan (Qiu et al. 2007) . We showed that the sulfated glucan WSS25 was a new candidate drug that inhibited hepatocarcinoma cell growth. This polysaccharide could bind to bone morphogenetic protein-2 (BMP2) to suppress tube formation in human microvascular endothelial cells (HMEC-1) and affected the DNA-binding-protein inhibitor, Id1 and expression of other angiogenic genes, thereby influencing cancer cell growth (Qiu et al. 2010) . However, its mechanism of action is still largely unknown. We demonstrated that the sulfated polysaccharide heparin inhibited expression of the proangiogenesis factor miR-10b in HMEC-1 cells (Shen et al. 2011) . This evidence suggests that sulfated polysaccharides might regulate angiogenesis associated with miRNAs. We, therefore, hypothesized that the disruption of angiogenesis caused by WSS25 might be mediated by miRNA function. In this study, we discovered that the proangiogenesis factor Dicer was inhibited by WSS25. Furthermore, we reported that miR-210 expression and its proangiogenesis function were inhibited by WSS25. Finally, we demonstrated that WSS25 inhibited angiogenesis through influencing Dicer, miR-210 and Ephrin-A3 function in angiogenesis.
Results

WSS25 influences expression of miRNAs in HMEC-1 cells
To explore whether the antiangiogenesis effects of WSS25 were linked to miRNA function, we first analyzed the expression of human miRNAs by genome-wide miRNA screening in HMEC-1 cells treated with WSS25. We found that expression of many miRNAs was affected by WSS25. The miRNA profiling studies revealed that 25 miRNAs were significantly upregulated in WSS25-treated HMEC-1 cells, including miR-126, 105, 204, 215, 96, 580, 567, 92b, 222*, 16-1*, 129-5p, 135b*, 518b, 30c-1*, 557, 27b*, 127-3p, 638, 125b-2*, 29a*, 1249, 1207-3p, 664, 20a and 513b (Table I ).
In contrast, 12 miRNAs were significantly downregulated, including miR-29a, 378, 10a, 124, 708*, 181a-2*, 216a, 432*, 631, 339-5p, 210 and 508-5p (Table I) . Several of these miRNAs, miR-126, 20a, 378 and 210, have been reported to be involved in angiogenesis (Lee et al. 2007; Fasanaro et al. 2008; Pulkkinen et al. 2008; Waldman and Terzic 2009; Wang and Olson 2009; Doebele et al. 2010; Staszel et al. 2011 ).
WSS25 inhibits Dicer expression, while knockdown of Dicer suppresses tube formation and miR-210 expression, and enhances Ephrin-A3 expression Since the expression of >37 miRNAs was influenced by WSS25, we supposed that components of the miRNA biogenesis machinery might be regulated by WSS25. To address this hypothesis, we next examined whether Dicer, the enzyme that controls miRNA biosynthesis, was involved in the inhibition of angiogenesis by WSS25. The expression level of Dicer was determined in HMEC-1 cells treated with WSS25. As shown in Figure 1A , Dicer was expressed in HMEC-1 cells and its expression was blocked by WSS25. To examine whether knockdown of Dicer would mimic the effects of WSS25 on HMEC-1 cell tube formation, siRNAs were designed against Dicer (Kuehbacher et al. 2007; Suarez et al. 2007 ). Reverse transcription-PCR (RT-PCR) and Western blotting confirmed the efficient and specific suppression of Dicer by the siRNA oligonucleotides ( Figure 1B) . In order to assess the role of Dicer in angiogenesis, we measured HMEC-1 cell tube formation after silencing of Dicer with siRNA. As shown in Figure 1C , HMEC-1 cell tube formation was almost completely disrupted by Dicer siRNA. This result was consistent with previous reports that knockdown of Dicer significantly reduced tube-forming activity in HUVEC (Kuehbacher et al. 2007 ). However, it was not clear from these results which specific miRNA was regulated by Dicer in HMEC-1 cells. Since the results of genome-wide miRNA screening indicated that miR-210 was significantly downregulated by WSS25 in HMEC-1 cells, and miR-210 has been reported to be implicated in HUVEC cell tube formation through targeting of Ephrin-A3, we next evaluated whether the inhibition of Dicer might influence miR-210 and Ephrin-A3 expression using quantitative real-time PCR. Intriguingly, the expression of miR-210 was markedly downregulated by Dicer siRNA ( Figure 1D ), and the expression of Ephrin-A3 was significantly increased ( Figure 1E ). These results suggested that regulation of the function of Dicer, its product miRNA, miR-210 and Ephrin-A3 might mediate the antiangiogenic effects of WSS25.
Dicer enhances tube formation and miR-210 expression while suppressing Ephrin-A3 expression In order to further investigate the role of Dicer in angiogenesis, Dicer overexpression plasmid was employed to evaluate its effect on HMEC-1 cell tube formation. First, the overexpression efficiency was confirmed by RT-PCR ( Figure 2A ) and Western blotting ( Figure 2B ). Interestingly, tube formation was significantly induced by Dicer ( Figure 2C ). We then determined whether overexpression of Dicer could affect miR-210 and Ephrin-A3 expression using quantitative real- The HMEC-1 cells were treated with WSS25 (25 µg/mL) for 18 h followed by whole genome miRNA screening as described in Materials and methods. The miRNA was considered up-or downregulated if the fold change in expression level detected in WSS25-treated HMEC-1 cells versus normal HMEC-1 cells was ≥1.5 or ≤0.67, respectively.
Targeting miRNA to inhibit angiogenesis time PCR. The results showed that Dicer significantly enhanced the expression of miR-210 ( Figure 2D ) and correspondingly decreased the expression of Ephrin-A3 ( Figure 2E ). These findings suggested that Dicer might act as a proangiogenic gene that is affected by WSS25-mediated inhibition of angiogenesis.
WSS25 inhibits the expression of miR-210 and endogenous miR-210 silencing suppresses angiogenesis Although WSS25 impaired Dicer function, while Dicer augmented miR-210 expression, it was still unclear from these results whether miR-210-mediated angiogenesis was regulated by WSS25. The microarray results described above demonstrated that miR-210 expression was inhibited by WSS25. Suppression of miR-210 expression by WSS25 (25 µg/mL) in HMEC-1 cells was further confirmed by RT-PCR ( Figure 3A ). Next, we investigated whether miR-210 was implicated in HMEC-1 cell tube formation. To address this question, manipulation of miR-210 expression was carried out. Firstly, anti-miR-210 was transfected into HMEC-1 cells to silence miR-210 expression. As expected, miR-210 expression was significantly decreased by anti-miR-210 ( Figure 3B ). HMEC-1 cell migration and tube formation were then measured in cells transfected with anti-miR-210. As shown in Figure 3C , HMEC-1 cell motility was significantly reduced by anti-miR-210 in a wound-healing assay when compared with that in the sham-transfected group. Similarly, the number of branch points and tube formation were also less than those in the sham group ( Figure 3D ). This suggested that suppression of miR-210 reduces cell migration and capillary-like network formation in HMEC-1 cells. To elucidate whether transfection with miR-210 would have the opposite effect on angiogenesis, miR-210 and control vector (Mock) were transfected into HMEC-1 cells. MiR-210 expression was highly induced in transfected HMEC-1 cells compared with that in the mock transfected cells (Supplementary data, Figure S1A ). In Supplementary data, Figure S1B , we show that overexpression of miR-210 led to an enhancement of wound-healing recovery when compared with the mock group. Concomitantly, more capillary-like structures were formed in the miR-210 overexpressing cells (Supplementary data, Figure S1C ). The above data suggested that miR-210 may act as a proangiogenic factor in HMEC-1 cells. were seeded into a 6-well plate, incubated for 24 h and then treated with 25 µg/mL of WSS25 for 18 h. Dicer mRNA and protein expression were then detected by RT-PCR and Western blotting using 18S rRNA as an internal control and β-actin as a control for protein loading, respectively. All experiments were repeated three times. (B) HMEC-1 cells were incubated in a 6-well plate for 24 h before transfection with siRNA against Dicer. Both RT-PCR and Western blotting were used to detect Dicer expression after transfection for 48 h. (C) Tube formation by HMEC-1 cells on Matrigel was measured after Dicer siRNA transfection, compared with blank and sham controls. (D) and (E) miR-210 expression (D) and Ephrin-A3 expression (E) were assessed after Dicer knockdown using quantitative real-time PCR. *P < 0.05 and **P < 0.01.
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Ephrin-A3 is a functional target of miR-210 in HMEC-1 cells To determine the mechanisms by which miR-210 induces angiogenesis, we evaluated potential targets of miR-210 using public algorithms. Computational prediction provided by TargetScan, PicTar and miRanda (John et al. 2006; Creighton et al. 2008 ) revealed a group of genes that were possible targets of miR-210. These candidates included Ephrin-A3, which was predicted as a potential target of miR-210 by all the three online search programs. The sequence alignment in Supplementary data, Figure S2A , demonstrates that miR-210 is partially complementary to the RNA sequence extending from nucleotide 783-806 within the 3′UTR of human Ephrin-A3. To determine whether miR-210 directly targets the 3′UTR of Ephrin-A3, we constructed a luciferase reporter vector that encoded the complete 3′UTR of this gene. The vector was then co-transfected with miR-210 into Human Embryonic Kidney 293 (HEK293) cells. We found that the activity of the luciferase reporter gene fused to the 3′UTR of Ephrin-A3 was reduced by >5-fold (Supplementary data, Figure S2B ). To provide further confirmation of the target, the luciferase reporter gene fused to the 3′UTR of Ephrin-A3 was co-transfected with anti-miR-210 into HEK293 cells. The luciferase activity was indeed promoted by anti-miR-210 in a dose-dependent manner (Supplementary data, Figure S2C ). Meanwhile, Ephrin-A3 protein expression was increased following transfection of anti-miR-210 into HMEC-1 cells to silence miR-210 expression (Supplementary data, Figure S2D ), but was strongly attenuated by miR-210 overexpression in HMEC-1 cells (Supplementary data, Figure S2E ). These results suggested that Ephrin-A3 was indeed a direct target of miR-210. The results were also in agreement with previous reports by Fasanaro et al. (2008) and Pulkkinen et al. (2008) regarding the target of miR-210. While tube formation was inhibited by anti-miR-210 as expected, expression of the target molecule Ephrin-A3 was enhanced. Next, we investigated the role of Ephrin-A3 in tube formation by manipulating its expression using Ephrin-A3 overexpression plasmid and siRNA against Ephrin-A3. The Ephrin-A3 gene and Ephrin-A3 siRNA were constructed into the pLVX-internal ribosome entry site (IRES)-ZsGreen1 vector and pll3.7, respectively. Viruses carrying Ephrin-A3 and Ephrin-A3 siRNA and their vector controls were produced by transfecting HEK293T cells with viral packaging vectors. The resulting viruses were then used to infect HMEC-1 cells. The efficient and specific enhancement and suppression of Ephrin-A3 were first demonstrated using RT-PCR and Western blotting. As expected, transfection of Ephrin-A3-containing plasmids led and Ephrin-A3 expression (E) were determined after Dicer transfection as described in (A) and (B) using quantitative real-time PCR, compared with blank and mock controls. *P < 0.05 and **P < 0.01.
Targeting miRNA to inhibit angiogenesis to overexpression of Ephrin-A3 in HMEC-1 cells at mRNA ( Figure 4A ) and protein ( Figure 4B ) levels. Meanwhile, Ephrin-A3 expression was silenced by Ephrin-A3 siRNA at both mRNA ( Figure 4C ) and protein ( Figure 4D ) levels. Functional studies indicated that Ephrin-A3 could significantly inhibit HMEC-1 cell tube formation ( Figure 4E ), while a reduction in Ephrin-A3 expression promoted tube formation ( Figure 4F ). These results showed that Ephrin-A3 does appear to play a functional role in tube formation.
WSS25 promotes Ephrin-A3 expression
The above results suggested that WSS25 reduced Dicer and miR-210 expression, whereas the silencing of Dicer downregulated miR-210 expression and upregulated Ephrin-A3 expression. We, therefore, proposed that Ephrin-A3 expression might be induced by WSS25. To test this hypothesis, HMEC-1 cells were treated with 25 µg/mL of WSS25 for 18 h followed by quantitative real-time PCR and Western blotting. Expression of Ephrin-A3 mRNA was indeed augmented >2-fold ( Figure 4G ), while there was 2-fold increase in protein expression ( Figure 4H ). Previous results using an oligo-angiogenesis microarray assay also showed that Ephrin-A3 expression was induced by WSS25 in HMEC-1 cells (data not shown). The promotion of this antiangiogenic gene by WSS25 was consistent with the microarray data.
Dicer, miR-210 and Ephrin-A3 siRNA partially rescue the inhibition of HMEC-1 cell tube formation caused by WSS25 WSS25 downregulated Dicer and miR-210 expression and upregulated the expression of the miR-210 target gene Ephrin-A3. In order to understand whether the inhibition of HMEC-1 cell tube formation by WSS25 was indeed mediated by downregulation of Dicer and miR-210 and upregulation of Ephrin-A3, we first incubated HMEC-1 cells with or without WSS25 (25 and 50 µg/mL) before conducting a tube formation assay. We found that WSS25 disrupted tube formation ( Figure 5A ). Next, Dicer, miR-210 or siRNA against Ephrin-A3 were transfected into HMEC-1 cells, which were then incubated with or without WSS25 (25 µg/mL) before use in quantitative real-time PCR and tube formation assays. We showed that WSS25 could inhibit Dicer and miR-210 expression even when these genes were overexpressed in HMEC-1 cells (Supplementary data, Figure S3A and B). In addition, WSS25 could also enhance Ephrin-A3 expression even when Ephrin-A3 expression had been silenced by transfection with siRNA against Ephrin-A3 (Supplementary data, Figure S3C ). WSS25 at concentrations of 25 and 50 µg/mL almost completely disrupted the enclosed capillary networks formed by HMEC-1 cells, in comparison with the control group, while this was not the case in HMEC-1 cells overexpressing Dicer ( Figure 5B ) and miR-210 ( Figure 5C ) or with silenced Ephrin-A3 ( Figure 5D ). This suggested that tube formation arrested by WSS25 could be partially counteracted by Dicer, miR-210 or silencing of Ephrin-A3.
Discussion
WSS25 has been validated as angiogenesis inhibitor (Qiu et al. 2010) . It can disrupt HMEC-1 cell migration and tube formation in vitro and also inhibit growth of xenografted hepatocellular cancer cells in nude mice in vivo through blocking the BMP/Smad/Id1 signaling pathway (Qiu et al. 2010) . Although WSS25 may target BMP2 and its receptors to block angiogenesis, it seems that many factors are involved in this process (Qiu et al. 2010) . For instance, WSS25 has been shown to induce chemokine (C-X-C motif ) ligand 2 (CXCL2), CXCL5, Ephrin-B2, Interleukin 12A (IL12A), platelet-derived growth factor beta polypeptide (PDGFβ) and phosphatase and tensin homolog (PTEN), while inhibiting plasminogen activator, tyrosine kinase, endothelial (TEK) and Notch homolog 4 (NOTCH4) (Qiu et al. 2010) , as well as miRNAs. In this study, we found that WSS25 also suppressed Dicer and miR-210 expression while enhancing Ephrin-A3 expression. Meanwhile, we confirmed that miR-210 positively modulates the angiogenic activity of HMEC-1 cells by decreasing Ephrin-A3 expression, since miR-210 induced HMEC-1 cell migration and tube formation, while silencing it inhibited cell migration and tube formation. Using WSS25 as a probe, we also showed that Dicer promoted miR-210 and inhibited Ephrin-A3 function to induce HMEC-1 cell tube formation. These findings suggest a new pathway involving both Dicer and miR-210 in the mechanism underlying the antiangiogenesis effect elicited by WSS25.
Dicer is an endoribonuclease in the RNase III family that cleaves double-stranded RNA (dsRNA) and pre-miRNA into short dsRNA fragments (Macrae et al. 2006; Martello et al. 2010) . Dicer and other miRNA-processing enzymes may play important roles in cancer prognosis (Slack and Weidhaas 2008) . Two research groups (Kuehbacher et al. 2007; Suarez et al. 2007 ) have shown that reduction of miRNA levels via Dicer silencing strongly impacts on endothelial cell function in vitro, suggesting a critical role for Dicer and its downstream miRNAs in angiogenesis. However, it is not well understood which specific miRNA is regulated by Dicer to influence angiogenesis. In this study, we first showed that WSS25 had a potent effect on the expression level of Dicer. Since we observed that WSS25 could inhibit Dicer expression at both mRNA and protein levels ( Figure 1A ) and the inhibition of Dicer expression was dose-dependent (Supplementary data, Figure S4 ), we first speculated that WSS25 might inhibit the transcription of Dicer. According to the literature, Sry-related high-mobility group box4 transcription factor (Sox4) positively regulates Dicer expression by binding to its promoter sequences and enhancing its activity (Scharer et al. 2009; Jafarnejad et al. 2012) . Microphthalmia-associated transcription factor (MITF) has been reported to bind and activate a conserved regulatory element upstream of Dicer's transcriptional start site (Levy et al. 2010) , while TAp63, a p53 family member, has been demonstrated to be a direct transcriptional regulator of Dicer through binding to and transactivating the Dicer promoter (Su et al. 2010) . To test whether inhibition of Dicer expression by WSS25 was at transcription level, we examined the expression levels of Sox4, MITF and TAp63 after WSS25 treatment in HMEC-1 cells using RT-PCR. Interestingly, the expression of Sox4, MITF and TAp63 were all downregulated (Supplementary data, Figure S5A ). These results clearly indicated that the expression levels of the transcription factors of Dicer were inhibited after WSS25 treatment. In addition, we used the pGL3-Dicer-promoter plasmid to identify the effect of WSS25 on the Dicer-promoter region. The results indicated that the luciferase activity of the pGL3-Dicer-promoter was 74-fold compared with pGL3-Basic (Supplementary data, Figure S5B ). The luciferase activity of the pGL3-Dicer-promoter was reduced to 72 and 52% of control values after treatment with 25 and 50 µg/mL of WSS25, respectively (Supplementary data, Figure S5B ). To investigate whether WSS25 also influenced the degradation of . HMEC-1 cell tube formation was examined after Ephrin-A3 overexpression. The statistical analysis of tube length is shown in the graph in the right hand column. (F) HMEC-1 cells were infected as described in (C) and (D), followed by tube formation assay after Ephrin-A3 knockdown. The statistical analysis of tube length is shown in the graph in the right hand column. (G) and (H) HMEC-1 cells were incubated with or without 25 µg/mL WSS25 for 18 h. Ephrin-A3 mRNA (G) and protein (H) expression were determined using quantitative real-time PCR and Western blotting, with 18S rRNA and β-actin as loading controls, respectively. All experiments were repeated three times. *P < 0.05 and **P < 0.01.
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Dicer, Cycloheximide (CHX), which is an inhibitor of protein biosynthesis in eukaryotic organisms produced by the bacterium Streptomyces griseus, was used to evaluate the stability of Dicer. The HMEC-1 cells were treated with 100 µg/mL CHX alone or a mixture of 25 µg/mL WSS25 and 100 µg/mL CHX for 0, 15, 30, 60, 90 or 120 min. The expression of Dicer was determined by Western blotting. Interestingly, the expression of Dicer was not significantly changed after treatment with CHX or a mixture of WSS25 and CHX for 0, 15, 30, 60, 90 or 120 min. The results suggested that the Dicer protein was stable and it seems that WSS25 could not significantly influence the degradation of Dicer (Supplementary data, Figure S5C ). Although the data showed that suppression of Dicer by WSS25 might be mediated by transcription factors for Dicer, the mechanism is still unclear. For instance, it is unclear how WSS25, a large polyanionic polysaccharide, is able to bind to transcription factors when macromolecules cannot penetrate the cell membrane by passive diffusion. However, we have observed that polysaccharides, including WSS25, can be engulfed by the cell membrane and drawn into the cell. This internalization appeared to be mediated by clathrin, Eps15 and dynamin functional proteins in intestinal Caco-2, HIMC and tumor cells (unpublished data). It is, therefore, theoretically possible that WSS25 might gain access to transcription factors through this type of endocytosis. Alternatively, as we have previously reported, WSS25 may bind to receptors (such as BMPs) on the cell membrane, triggering signaling pathways that influence the function of nuclei factors (Qiu et al. 2010) .
Next, we showed that the suppression of Dicer could significantly downregulate specific miR-210 expression ( Figure 1D ), while Dicer itself enhanced tube formation and miR-210 expression and suppressed Ephrin-A3 expression ( Figure 2C-E) . The finding that HMEC-1 cell tube formation which was blocked by WSS25 could be partially rescued by overexpression of Dicer or miR-210 or silencing of Ephrin-A3 (Figure 5 ), when taken together with the above data, led us to the conclusion that WSS25 inhibited angiogenesis by blocking Dicer, leading to downregulation of miR-210, thereby causing upregulation of Ephrin-A3. In the previous studies, we found that WSS25 disrupted angiogenesis through BMP/Smad/Id1 signaling (Qiu et al. 2010 ), and we have now shown that WSS25 might inhibit HMEC-1 cell tube formation through a Dicer/miR-210/Ephrin-A3 pathway. To evaluate whether BMP/Smad/Id1 signaling was linked to the effects of Dicer, we tested the effect of Noggin, which is an endogenous BMP2 antagonist and further blocks BMP/ Smad/Id1 signaling on the expression levels of Dicer and the transcription factors of Dicer using RT-PCR. The results indicated that the expression levels of Sox4, MITF, TAp63 and Dicer were not significantly changed after treated with Noggin for 18 h in HMEC-1 cells (Supplementary data, Figure S6 ). It seems that the Dicer/miR-210/Ephrin-A3 pathway involved in the antiangiogenesis effect mediated by WSS25 was independent of the BMP/Smad/Id1 signaling pathway we have previously reported. This may be the first evidence that a sulfated polysaccharide can inhibit Dicer expression and that Dicer induces HMEC-1 cell tube formation through producing specific miRNA to regulate Ephrin-A3. However, whether the angiogenesis induced by Dicer facilitates tumorigenesis is not yet clear, since metastatic breast tumors resistant to Tamoxifen (Tam, the most prescribed hormonal agent for treatment of estrogen receptor α (ERα)-positive breast cancer patients) therapy had elevated levels of Dicer (Selever et al. 2011) . This indicates that the role of Dicer in tumor development may be multiple and complex based on the fact that this enzyme is involved in the biosynthesis of many miRNAs that regulate different target genes. Recently, several studies have reported miR-210 to be one of the highly upregulated miRNAs in hypoxic cells (Mathew and Simon 2009 ). Huang et al. (2009) first performed miRNA microarray profiling in hypoxic pancreatic cell lines and identified miR-210 as the most highly upregulated species. Furthermore, other groups have demonstrated that hypoxia induced miR-210 expression in breast, head and neck, lung, liver and renal cell lines, indicating a broad hypoxic response (Gee et al. 2010; Nakada et al. 2011; Rothe et al. 2011; Wang et al. 2011; Ying et al. 2011) . Nevertheless, the role of miR-210 in angiogenesis is not well understood, with the exception of the report by Fasanaro et al. (2008) in hypoxia. In our study, the impact of miR-210 on angiogenesis was examined using two different bioassays-the in vitro cell migration and tube formation assays. Though these assays cannot represent the whole process of angiogenesis, they mimic the different stages of angiogenesis and reflect the complex behavior required for angiogenesis by endothelial cells (Lawley and Kubota 1989) . The migration and tube formation abilities of normal HMEC-1 cells were decreased after transfection with miR-210 inhibitor ( Figure 3C and D) . In addition, overexpression of miR-210 in HMEC-1 cells was found to enhance HMEC-1 cell migration and the formation of tube-like structures in normoxic conditions (Supplementary data, Figure S1B and C). These data suggested that endogenous miR-210 acted as an enhancer in HMEC-1 cell migration and tube formation. These results add to new accumulating evidence that miR-210 plays a role in the process of angiogenesis.
To date, >200 miRNAs have been shown to be expressed by endothelial cells (Wurdinger et al. 2008; Chai et al. 2009; Heusschen et al. 2010) . Several miRNAs have been reported to be involved in angiogenesis, including miR-210, miR-126, miR-20a and miR-378 (Lee et al. 2007; Fasanaro et al. 2008; Pulkkinen et al. 2008; Waldman and Terzic 2009; Wang and Olson 2009; Doebele et al. 2010; Staszel et al. 2011) . In this study, miR-210 was confirmed to be involved in the regulation of angiogenesis inhibited by WSS25. In addition, miR-378, another proangiogenesis miRNA, was also downregulated by WSS25 (Supplementary data, Figure S7A ). It is reported that miR-378 promotes cell survival, tumor growth and angiogenesis by targeting two tumor suppressors, suppressor of fused (SuFu) and Fus-1 (Lee et al. 2007 ). SuFu is a major component in the Hedgehog pathway, a pathway that plays important roles in both development and cancer (Humke et al. 2010) . Fus-1, also known as tumor suppressor candidate 2 (TUSC2), is a tumor suppressor gene located on human chromosome 3p21.3, a region in which deficient gene expression is frequently seen in lung cancer expression (Prudkin et al. 2008) . Transfection of SuFu and Fus-1 constructs reversed the effect of miR-378 on tumor cell survival (Lee et al. 2007 ). However, the detailed mechanism underlying the effect of miR-378 on angiogenesis was still not clear. To address whether miR-378 was involved in angiogenesis in our study, anti-miR-378 was transfected into HMEC-1 cells to silence miR-378 expression. The results showed that miR-378 expression was significantly decreased by anti-miR-378 (Supplementary data, Figure S7B ) and the reduction of miR-378 significantly inhibited HMEC-1 cell migration (Supplementary data, Figure S7C ) and tube formation (Supplementary data, Figure S7D ). Meanwhile, miR-20a was upregulated after WSS25 treatment by the miRNA array, and miR-20a is considered an antiangiogenesis miRNA through downregulating vascular endothelial growth factor (VEGF), which is a pivotal angiogenic factor (Hua et al. 2006) . Therefore, in addition to miR-210, there might be more miRNAs involved in the regulation of angiogenesis inhibited by WSS25. However, miR-10b, which has also been shown to mediate heparin-induced angiogenesis in vitro and in vivo (Shen et al. 2011) , was not affected by WSS25 (data not shown). These results suggested that the structural motif of the polysaccharide might play an important role in miRNA-mediated angiogenesis, although both WSS25 and heparin are sulfated glycans. These results also indicated that the angiogenesis arrest caused by WSS25 was mediated by angiogenesis factors combined with miRNAs.
Ephrin-A3, a member of the ephrin (EPH) family, is a protein that in humans is encoded by the EFNA3 gene (Cerretti et al. 1996) . The function of Ephrin-A3 has mainly been studied in the field of neuroscience, in axon targeting, hippocampal dendritic spine morphology and glutamate transport Filosa et al. 2009; Stein et al. 1999) . Nevertheless, little has been reported concerning the role of Ephrin-A3 in angiogenesis. In this study, we demonstrated that WSS25 could upregulate Ephrin-A3 and that this was the target of miR-210. As Ephrin-A3 is the direct target of miR-210 and miR-210 plays an important role in angiogenesis, we further demonstrated that Ephrin-A3 contributed to angiogenesis ( Figure 4E and F) . Recent research has shown that Ephrin-A3 binds to heparan sulfate, while the presence of cell surface heparan sulfate is required for the full biological activity of Ephrin-A3 (Irie et al. 2008) . In this study, we provided evidence that the heparan sulfate mimetic polysaccharide WSS25 regulated the function of Ephrin-A3 in angiogenesis. Although the results showed that the effects of enhancement and reduction of Ephrin-A3 on tube formation were significant, miR-210 may also regulate other target genes that modulate angiogenesis in addition to Ephrin-A3, such as hypoxia-induced factor-1α (HIF-1α) (http://www. microrna.org/microrna/), neuronal pentraxin 1 (NPTX1) (Pulkkinen et al. 2008) , vacuole membrane protein 1 (VMP1) (Ying et al. 2011 ) and fibroblast growth factor receptor-like 1 (FGFRL1) (Tsuchiya et al. 2011) . VMP1 hinders the migration and invasion of hepatocellular carcinoma (HCC) cells, and restoration of VMP1 can abrogate the migration and invasion of HCC cells induced by miR-210. HIF-1α is considered to be a proangiogenesis factor. FGFRL1 accelerates cancer cell proliferation by preventing cell cycle arrest in G1/G0. Human NPTX1 mRNA is exclusively localized in the nervous system. Nevertheless, this is the first demonstration of the role of Ephrin-A3 in tube formation. Since the expression of Ephrin-A3 was promoted by WSS25, we further investigated the effects of WSS25 on the expression of HIF-1α, NPTX1, VMP1 and FGFRL1. The results showed that WSS25 upregulated HIF-1α expression and downregulated NPTX1, VMP1 and FGFRL1 expression (Supplementary data, Figure S8 ). These results were inconsistent with those for Ephrin-A3. Since WSS25 increased the expression of Ephrin-A3, which exhibited an antiangiogenesis effect, theoretically, the expression of NPTX1, VMP1 and FGFRL1 should be upregulated by WSS25 and HIF-1α, which is considered a proangiogenesis factor, should be downregulated after WSS25 treatment. We, therefore, speculated that Ephrin-A3 was one of key target genes of miR-210 during angiogenesis.
To test whether the reduction of endothelial cell tube formation was more than a nonspecific effect on cell growth, we measured cell viability using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. As shown in Supplementary data, Figure S9 , a reduction in Dicer (Supplementary data, Figure S9A ), miR-210 or miR-378 (Supplementary data, Figure S9B ) did not affect cell viability after the cells were transfected by Dicer siRNA, anti-miR-210 or anti-miR-378 for 24, 48 or 72 h. Similarly, the enhancement of Ephrin-A3 (Supplementary data, Figure S9C ) did not impair cell viability during treatment for up to 72 h. Furthermore, there was no significant effect of WSS25 on the proliferation of HMEC-1 cells at concentrations ≤50 µg/mL up to 72 h (Supplementary data, Figure S9D ).
In summary, we report here that WSS25, a heparan sulfate mimetic, inhibited tube formation by decreasing miR-210 expression and increasing expression of the miR-210 target gene Ephrin-A3. This inhibition of miR-210 expression was due, at least partly, to blocking of the expression of Dicer, a Targeting miRNA to inhibit angiogenesis component of the miRNA biogenesis machinery. This study provides the first evidence concerning the role of Dicer and miRNA probed by polysaccharide in mediating HMEC-1 cell behavior. These findings add to new evidence that WSS25 not only modulates angiogenesis factors and the BMP/Smad/Id1 signaling pathway, but also influences miRNA function. This study advances our understanding of the actions of WSS25 in the area of angiogenesis and even provides further insight into potential WSS25-based new drug development in terms of miRNAs.
Materials and methods
General materials WSS25 was prepared in this laboratory as described previously (Qiu et al. 2007 ) and then dissolved in normal saline for experimental use after passing through a 0.22 µm filter. Matrigel containing growth factors was obtained from BD Biosciences (Bedford, MA). CHX and Noggin were purchased from Beyotime (Beyotime Institute of Biotechnology, Nantong, Jiangsu, China) and PrimeGene (Shanghai PrimeGene Bio-Tech Co., Ltd., Shanghai, China), respectively, and were dissolved according to the manufacturer's instructions.
Cell culture HMEC-1 cells were cultured in MCDB 131 medium (GIBCO-BRL; Grand Island, NY) containing 15% fetal bovine serum (FBS) (v/v; Sijiqing Co., Ltd., Hangzhou, Zhejiang, China), 2 mM L-glutamine, 10 ng/mL epidermal growth factor (EGF; Shanghai PrimeGene Bio-Tech Co., Ltd., Shanghai, China), 100 U/mL penicillin and 100 µg/mL streptomycin (Gibco BRL). HEK293 and HEK293T cells were maintained in Dulbecco's modified Eagle's medium (DMEM; HyClone, Thermo Scientific; Waltham, MA) with 10% FBS. All the cells were cultured in a humidified incubator at 37°C with 5% CO 2 .
MiRNA microarray analysis HMEC-1 cells were seeded in 60-mm culture dishes for 24 h and then treated with 25 µg/mL WSS25 for 18 h. Control cultures without WSS25 were performed in parallel. Total RNA was extracted using 1.5 mL Trizol reagent (Invitrogen; Carlsbad, CA) and an RNeasy Mini Kit (Qiagen; Venlo, Netherlands p/n 74104) according to the manufacturer's protocol. The quantity of RNA was determined by measuring optical density at 260 nm using the Eppendorf BioPhotometer Plus (Eppendorf, Hamburg, Germany). Quantified RNA was double labeled with Hy3™ and Hy5™, using a miRCURY™ labeling kit (Cat #208032-A, Exiqon, Vedbaek, Denmark). The labeled RNA was hybridized with the chip, washed using a miRCURY™ washing kit (Cat #208021, Exiqon, Denmark) and centrifuged at 200 × g. When the labeled RNA was dry, a microarray scanner (Axon GenePix 4000B) was used to scan the chip. The results were analyzed using the GenePix pro V6.0 software.
Cell transfection
The siRNA against Dicer (si-Dicer) was obtained from RiboBio (RiboBio Co., Ltd., Guangzhou, Guangdong, China). Dicer plasmid was purchased from Sino Biological Inc. (Beijing, China). The miR-210 inhibitor (anti-miR-210) and miR-378 inhibitor (anti-miR-378) were obtained from GenePharma (GenePharma Co., Ltd., Shanghai, China). The miR-210 precursor plasmid (miR-210) was provided by Professor Songshan Jiang's laboratory at Zhongshan University (Guangzhou, Guangdong, China). To silence Dicer, we used the published sequences of siRNA (siRNA Dicer 1 and 2), which were 5′-UGCUUGAAGCAGCUCUGGA-3 (si-Dicer-1) and 5′-UUUGUUGCGAGGCUGAUUC-3′ (siDicer-2) (Kuehbacher et al. 2007 ). The sequences of 2′-Omethyl anti-miR-210 and anti-miR-378 were 5′-UCAGCCGC srUGUCACACGCACAG-3′ and 5′-CCUUCUGACUCCAAG UCCAGU-3′, respectively. Scrambled 2′-O-methyl modified RNA (5′-CAGUACUUUUGUGUAGUACAA-3′) was used as a negative control. Transfection of DNA (plasmids) and RNA (miRNA inhibitors and siRNAs) was performed using the FuGENE HD transfection reagent (Roche; Basel, Switzerland) and Lipofectamine™ 2000 (Invitrogen), respectively, according to the manufacturer's instructions.
Lentivirus-based overexpression and knockdown
Virus-based overexpression and knockdown of Ephrin-A3 was conducted using the pLVX-IRES-ZsGreen1 vector and the pll3.7 vector, respectively. The Ephrin-A3 plasmid was purchased from IBSBio (Shanghai Integrated Biotech Solutions Co., Ltd., Shanghai, China). The effective target sequence for Ephrin-A3 knockdown was 5′-CGTGAACGA CTATCTGGAT-3′. Viruses carrying Ephrin-A3 or siRNA against Ephrin-A3 and their vector controls were produced by transfecting HEK293T cells with viral packaging vectors ( psPAX2, pMD2G), using a standard calcium phosphate transfection method. Virus was harvested from the supernatant of HEK293T cells 48 h posttransfection before being used to infect HMEC-1 cells. The cells were not used in any experiments until they had been cultured in complete medium without virus for 24 h.
RNA extraction, RT-PCR and quantitative real-time PCR
After transfection or WSS25 treatment, total RNA from cultured cells was extracted using Trizol reagent (Invitrogen) according to the manufacturer's protocol. Complementary DNA (cDNA) was generated from 2 µg of total RNA using Murine Leukemia Virus reverse transcriptase (M-MLV reverse transcriptase, TaKaRa; Otsu, Shiga, Japan). Semi-quantitative RT-PCR was performed to evaluate Dicer and Ephrin-A3 mRNA expression levels. The following primers were selected: Dicer, forward: 5′-CTGTGTACGATTGGCTGAA AG-3′ and reverse: 5′-CACTCTGGAATTGCTTTTGGG-3′; Ephrin-A3, forward: 5′-CTGGAAGTGTCTGAGGATGAA G-3′ and reverse: 5′-AGGCCAAGAACGTCATGAG-3′; 18S rRNA, forward: 5′-CGGCTACCACATCCAAGGAA-3′ and reverse: 5′-GCTGGAATTACCGCGGCT-3′. The expression levels of miR-210 and miR-378 were quantified using the Bulge-Loop™ miRNA qRT-PCR Primer Set (RiboBio Co., F Xiao et al. Ltd., Guangzhou, Guangdong, China) according to the manufacturer's instructions. PCRs were conducted using the following conditions: Denaturation at 94°C for 30 s, annealing at 63°C (Dicer)/64°C (Ephrin-A3) for 30 s and extension at 72°C for 30 s. Quantitative real-time PCRs were performed using an Applied Biosystems 7900 Fast Real-time PCR system with an SYBR Green Premix Ex Taq kit (TaKaRa, Japan). Real-time PCR cycle conditions included the following steps: For Dicer and Ephrin-A3, denaturation at 95°C for 20 s, followed by 40 cycles of denaturation at 95°C for 30 s, annealing at 63°C (Dicer)/64°C (Ephrin-A3) for 30 s and extension at 72°C for 30 s; for miR-210, denaturation at 95°C for 20 s, followed by 40 cycles of denaturation at 95°C for 10 s, annealing at 60°C for 20 s and extension at 72°C for 25 s. Each sample was run in triplicate and the Ct value was determined for the target transcripts, where Ct represents the threshold cycle for each transcript. Defined based on the Ct, relative miR-210 expression levels were calculated as 2 .
Western blotting analysis HMEC-1 cells treated under different conditions were lysed with an equal volume of RIPA buffer (0.5% Triton-X 100, 0.5% deoxycholic acid sodium salt, 0.1% sodium dodecyl sulfate (SDS) and 1% phenylmethanesulfonylfluoride (PMSF) supplemented with 1% proteinase inhibitor cocktail). Total protein content was determined by a protein assay according to the manufacturer's instructions (BioRad; Hercules, CA). Equivalent amounts of protein from each sample were separated by SDS-polyacrylamide gel electrophoresis and transferred to a polyvinyl difluoride (PVDF) membrane (BioRad). After blocking with TBST buffer (20 mM Tris [ pH 8.0], 150 mM NaCl and 0.1% Tween-20) containing 5% nonfat milk for 2 h, the membrane was incubated with antibodies against Dicer (Abcam; Cambridge, UK), Ephrin-A3 (Bioworld Technology; St. Louis Park, MN) and β-actin (Cell Signaling Technology; Beverly, MA) overnight at 4°C. Following incubation in horseradish peroxidase (HRP)-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, Inc.; West Grove, PA) for 2 h, enhanced chemiluminescence (ECL) Western blotting substrate (Pierce; Rockford, IL) was used for signal detection.
Tube formation assay A 96-well plate coated with 50 µL Matrigel per well was solidified at 37°C for 30 min. HMEC-1 cells (3 × 10 4 cells/well) were seeded into the plate and cultured in media containing 25 µg/mL or 50 µg/mL of WSS25 for 12 h. For transfection experiments, transfected or untransfected HMEC-1 cells were seeded onto the 96-well plate at 37°C for 12 h. Enclosed capillary networks of tubes were photographed using a microscope (Olympus IX51; Tokyo, Japan). In each well, five randomly selected fields of view were photographed and averaged to analyze for total capillary structure length using ImageJ.
Wound-healing assay HMEC-1 cells (5 × 10 5 cells/well) were seeded into a 6-well plate and incubated for 24 h. Cells were then transfected with DNA or RNA and their negative controls and incubated for a further 24 h. A wound in each well was then created by scratching the confluent monolayer layer with a yellow tip. After rinsing with phosphate buffered saline three times, cells were incubated with serum-free medium. Photos were taken immediately (t = 0 h) or 48 h later (t = 48 h) under a microscope (Olympus, IX51, Japan).
Dual luciferase reporter assays
The 3′ UTR luciferase reporter assay was performed using the pmiR-RB-Report™ vector (RiboBio Co., Ltd., Guangzhou, Guangdong, China). HEK293 cells were grown to approximately 70% confluence in 48-well plates and co-transfected with pmiR-RB-Report™-Ephrin-A3-3′UTR plus pll3.7-miR-210 or anti-miR-210 and their negative controls as described previously (Chen and Gorski 2008; Shen et al. 2011) . Cells were incubated with transfection reagent/DNA complex for 36 h followed by luciferase reporter assay using the Dual Luciferase Assay System (Promega; Madison, WI). Cell lysates were subjected to luciferase activity measurement according to the manufacturer's instructions. The human Dicer-promoter luciferase reporter assay was performed using the pGL3-Basic vector (Addgene; Cambridge, MA). HEK293 cells were plated in 48-well plates and co-transfected with pGL3-Dicer-promoter plus Renilla as an internal control or the negative control pGL3-Basic plus Renilla. Cells were incubated with transfection reagent/DNA complex for 6 h initially and then with 25 or 50 µg/mL WSS25 for 18 h, followed by luciferase assay as above.
MTT assay HMEC-1 cells were seeded at a density of 5 × 10 3 cells/well into a sterile 96-well plate and grown in 5% CO 2 at 37°C for 24 h. The cells were then transfected with different DNAs or RNAs and their negative controls or treated with WSS25 diluted to 6.25, 12.5, 25, 50, 100 or 200 µg/mL in culture medium. After transfection or treatment with different concentrations of WSS25 for 24, 48 or 72 h, cell viability was measured by MTT (MTT; Sigma-Aldrich, St. Louis, MO) assay as follows: 20 µL of 5 mg/mL MTT was added to each well and incubated with cells for 4 h in an incubator. The formazan was dissolved in 150 µL dimethyl sulfoxide (DMSO) following removal of the medium. Finally, the optical density was measured using a spectrophotometer (Thermo Multiskan MK3, Germany) at an absorption wavelength of 570 nm.
Statistical analysis
All results were expressed as the mean ± standard deviation (SD). The significance (P value) of the difference between groups was evaluated using a Student's t-test for comparison of two groups or one-way analysis of variance for multiple comparisons. Values of P < 0.05 were considered statistically significant (*P < 0.05 and **P < 0.01).
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